3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
18
Trastuzumab
7
Docetaxel
7
Paclitaxel
6
Magnetic Resonance Spectroscopy
5
Taxes
4
Drug Therapy
4
Carboplatin
4
Specimen Handling
3
Psychiatric Rehabilitation
3
Polymerase Chain Reaction
3
Nivolumab
3
Injections
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Cisplatin
3
Capecitabine
3
Biopsy
3
poly ICLC
2
fludarabine
2
durvalumab
2
belinostat
2
atezolizumab
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Lapatinib
2
Irinotecan
2
Interleukin-12
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
rocakinogene sifuplasmid
×
Breast
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled